Management 

Scott Koenig, M.D., Ph.D., President and Chief Executive Officer

Dr. Scott Koenig has been President and Chief Executive Officer of MacroGenics since September 2001.  Prior to joining MacroGenics, he served as Senior Vice President of Research at MedImmune Inc., where he participated in the selection and maturation of the company's product pipeline for 11 years. From 1984 to 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS.  Dr. Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston, where he was elected to Alpha Omega Alpha.  He completed his residency in Internal Medicine at the Hospital of the University of Pennsylvania and is Board certified in Internal Medicine and Allergy and Immunology.  Currently, he is Chairman of the Board of Directors at Applied Genetic Therapy Corporation, a private venture-backed biotechnology company in Alachua, FL developing genetic therapies using adeno-associated virus vectors.  Dr. Koenig is a member of the Board of Scientific Counselors at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health and was elected as a member of the Cornell University Council and the Emerging Companies Section Governing Body of BIO. 

Jean-Christophe Tellier, M.D., Executive Vice President and Chief Commercial Officer 

Dr. Tellier joins MacroGenics after a distinguished 20 year career in commercial development at Novartis.  Since February 2007, he served as Chairman and CEO of Novartis Pharma France and Novartis Group France.  The Group comprises 2,800 employees with sales at Novartis Pharma France of about €1 billion, including marketed brand name products in cardiovascular, oncology, neurosciences, respiratory, dermatology, transplant/immunology, infectious diseases, and ophthalmology.  Prior to this, Dr. Tellier was Head of the Global Business Franchise for Arthritis, Bone, and Muscle Disease headquartered in Basel.  From January 2003 through September 2006, Dr. Tellier served as CEO of Novartis Pharma Belgium and Country President where he was responsible for all business units and support services and coordination of all product sectors including OTC, generics, and Ciba Vision.  During this tenure, he became President of the Board of the Belgian Pharma Trade association (Pharma.be), the first non-Belgium citizen to be elected to this position.  Dr. Tellier received his M.D. from the University of Reims Champagne-Ardenne and a post-graduate degree in rheumatology from the University of Paris V.  In addition, he completed executive business programs at Harvard and INSEAD.   

James Karrels, Vice President, Chief Financial Officer

Mr. Karrels has over 15 years of experience in finance, including approximately ten years working for or on behalf of life science companies.  Prior to joining MacroGenics, he was at Jazz Pharmaceuticals, Inc., most recently serving as Executive Director of Finance, where he was responsible for the company’s financial planning and analysis and investor relations activities.  He began his career as an analyst at Merrill Lynch & Co. in 1989 and advanced to the position of Director in the Healthcare Investment Banking Group.  During his tenure at Merrill Lynch, he participated in more than 30 sole or lead-managed transactions, representing over $25 billion in aggregate transaction value.  His activities included the marketing, structuring and execution of IPOs, equity and convertible debt financings, mergers and acquisitions, spin-offs and other transactions.  Mr. Karrels holds an M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame.

Kathryn Stein, Ph.D., Senior Vice President, Product Development & Regulatory Affairs

Dr. Stein has over 22 years of experience at the FDA, working on all regulatory aspects of therapeutic proteins and monoclonal antibodies and was a leader in policy development at FDA for these products.  Most of the marketed monoclonal antibodies were approved under her leadership.  She maintained an active research lab at the FDA and played a significant role in the review and approval of the Hib conjugate vaccines.  Dr. Stein was VP, Product Development and Regulatory Affairs at MacroGenics from 2002-2005.  With the acquisition of a GMP manufacturing facility by MacroGenics in January 2005, Dr. Stein assumed the additional responsibility for Quality Assurance and Manufacturing.  Prior to her joining MacroGenics in 2002, she was Director, Division of Monoclonal Antibodies in the Office of Therapeutics Research and Review at CBER, a post she held from 1992.  During her time at the FDA, she received a number of awards and citations for her leadership on developing regulatory guidelines for therapeutic monoclonal antibodies and the FDA Award of Merit, its highest civilian award for her work on Haemophilus B conjugate vaccines.  The breadth and depth of Dr. Steins experience at the FDA are critical as MacroGenics pipeline candidates advance to the clinic and her familiarity with all aspects of monoclonal antibody and vaccine approval will ensure rapid and compliant submissions to the FDA for MacroGenics products.  Dr. Stein received her B.A. in Chemistry from Bard College in Annandale-on-Hudson, New York and her Ph.D. in Microbiology and Immunology from the Albert Einstein College of Medicine of Yeshiva University in the Bronx, New York.

Ezio Bonvini, M.D., Senior Vice President, Research

Dr. Bonvini comes to MacroGenics with 24 years of research, regulatory and clinical trial design experience spent at the National Cancer Institute, the National Institutes of Health, and more recently at the Food and Drug Administration (FDA) in the Center for Biologics Evaluation and Research (CBER), which is responsible for regulating therapeutic monoclonal antibodies and other proteins.  Dr. Bonvini's research dealt with the molecular mechanism of signal transduction by immune receptors in leukocyte activation.  During his tenure at CBER, he held several leadership positions in the Division of Monoclonal Antibodies, most recently as the Acting Deputy Division Director and Chief of the Laboratory of Immunobiology, where he was responsible for supervising the research program and the review of monoclonal antibody products from IND to BLA stages.  While at the FDA, Dr. Bonvini received several awards for his scientific and regulatory work.  His familiarity with all aspects of scientific, regulatory, and clinical development process for biologics will help focus MacroGenics R&D development of FDA-compliant product candidates from the earliest stages of preclinical development.  Dr. Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy, and his M.D., summa cum laude, and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine, in Genoa, Italy.

Ronald Wilder, M.D., Ph.D., Vice President, Clinical Research

Dr. Wilder, an internationally recognized rheumatologist/immunologist, has more than 30 years of research experience in the autoimmune and inflammatory diseases.  Prior to joining MacroGenics, Dr. Wilder served as the Vice President of Clinical Development at MedImmune, Inc., a publicly-traded biotech company which, like MacroGenics, focuses its research efforts on infectious diseases, cancer and autoimmune diseases.  Before moving to industry, Dr. Wilder was Chief of the Inflammatory Joint Diseases Program at the National Institutes of Health (NIH), capping a 25-year career with the institution.  Dr. Wilder obtained his M.D. and Ph.D. from the University of California, Los Angeles. He completed an internal medicine residency at the University of California San Diego before joining the NIH.  He is board certified in both internal medicine and rheumatology and is the author of more than 250 publications.

David A. Carlin, Ph.D., Vice President, Biostatistics & Data Management

Dr. Carlin has over 23 years of progressively responsible experience in the design and analysis of clinical trials in the pharmaceutical/biotechnology industry.  Prior to joining MacroGenics, he spent 11 years at MedImmune, Inc., where he held several leadership positions.  Dr. Carlin served as Vice President, Biostatistics and Data Management and Vice President, Clinical Research Design. He was responsible for the creation and management of the biostatistics, data management and statistical programming department, and was instrumental in the development and approval of MedImmune's marketed products.  While at MedImmune, Dr. Carlin provided expert strategic advice on clinical trial strategy for both pre-marketed and post-marketed compounds.  Before joining MedImmune, Dr. Carlin served as Director, Biostatistics and Data Information Systems, at Otsuka America Pharmaceutical and Director, Clinical Research, at Cetus Corporation.  Early in his career, Dr. Carlin held the position of lecturer at Golden Gate University and was a statistician at Warner Lambert/Parke-Davis.   He completed a postdoctoral fellowship at the University of North Carolina-Chapel Hill, Department of Biostatistics, where he was a Visiting Scholar supported by the National Heart, Lung and Blood Institute of the NIH. He has authored or co-authored several peer-reviewed publications.  Dr. Carlin obtained his Ph.D. and MS in Experimental Psychology at the Illinois Institute of Technology and his Bachelor of Science degree in Psychology from Drake University.

Stanley R. Pillemer, M.D., Vice President, Clinical Research and Product Safety

Dr. Pillemer is an internationally recognized rheumatologist with over 20 years of research experience and publications in the areas of rheumatic and autoimmune diseases.  Before joining MacroGenics, Dr. Pillemer was Senior Director, Clinical Development, at MedImmune.  He attended medical school in South Africa, and completed his training in Internal Medicine at the University of British Columbia, Vancouver, Canada, and in Rheumatology at the University of Toronto.  From 1984 to 2003, he worked at the National Institutes of Health, Bethesda, Maryland.  During this time he worked at the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) and performed studies on immunological and clinical aspects of systemic lupus erythematosus and other rheumatic disorders.  Subsequently, as a Medical Officer at the National Institute of Arthritis and Musculoskeletal and Skin Diseases, he conducted clinical trials and epidemiological studies and was involved in a number of programmatic activities.  After this, he headed the Sjogren's Syndrome Clinic, Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research in the Intramural Program at the National Institutes of Health, Bethesda, Maryland.  He designed and conducted clinical trials to investigate the role of immunomodulatory treatments in Sjogren's Syndrome (SS).  In addition, he worked with others to refine the classification criteria for SS, to develop outcome measures for clinical trials and long term studies of outcomes in SS, and to investigate the immunology and biology of SS.

Syd Johnson, Ph.D., Vice President, Antibody Engineering

Dr. Syd Johnson has 20 years of industrial experience encompassing all aspects of the antibody engineering field.  Prior to joining MacroGenics in 2001, he spent eleven years at MedImmune, Inc. where he led the preclinical effort to develop humanized monoclonal antibodies to respiratory syncytial virus (RSV).  Dr. Johnson is the inventor of Synagis, MedImmunes anti-RSV product, which is the only licensed monoclonal antibody product for prevention of viral infection.  Before that, he worked for six years at Genex Corporation (now a part of Enzon, Inc.) during which time he was instrumental in the development of single chain Fv technology for the production of antibody fragments in E. coli.

Joseph Panigot, J.D., Vice President, Legal Affairs

Mr. Panigot has almost 16 years of experience in the biotechnology and research products industries.  Prior to joining MacroGenics he served as the Director, Business Development and Legal Affairs at MedImmune, Inc.  He was the first in-house counsel at MedImmune and was responsible for establishing and building its legal and patent departments.  He was also responsible for strategic corporate development activities.  During his employment at MedImmune he directly negotiated or played significant roles in transactions totaling more than $20MM.  His professional experience prior to MedImmune includes serving in licensing and related technology transfer roles at the University of Maryland and in product development at Life Technologies, Inc.  Mr. Panigot obtained his B.S. in Biology from George Mason University, his M.S. in Forensic Science at The George Washington University and his J.D. from the University of Baltimore.  He is registered to practice before the U.S. Patent and Trademark Office and to practice law in D.C., Maryland and Virginia.

Robert Obst, Vice President, Human Resources & Operations

Mr. Obst has over 30 years of experience in building and managing the Human Resources and Environmental Health & Safety functions at MedImmune, Inc., W.R. Grace, Inc., SmithKline Beckman Corporation and American Cyanamid-Medical Group.  He is responsible for HR, EH&S, and Operations at MacroGenics. As head of HR and EH&S at MedImmune, Mr. Obst played a significant role in that Company's organizational development efforts, including the integration of two acquired companies. Mr. Obst received a BA in Sociology/Business from SUNY at Albany and his MBA in General Management from Pace University.

 Lynn Cilinski, Vice President and Controller

Ms. Cilinski has over 25 years experience in accounting and financial management with particular expertise in government accounting/auditing practices and procedures. Prior to joining MacroGenics in 2003, Ms. Cilinski was the Corporate Controller for three subsidiaries of Covanta Energy, Inc. (formerly known as Ogden Corporation) a large corporation performing services for both commercial clients and the federal government. Ms. Cilinski was responsible for all financial and administrative management and managed the operation of several divisions focused on all aspects of the accounting/administrative functions and overall operating systems. Ms. Cilinski has a BS in Accounting.